Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
Recruiting now · Phase 1/Phase 2
Conditions studied: Recurrent Prostate Cancer
In brief
The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Key facts
- Study ID
- NCT03067051
- Run by
- SpectraCure AB
- People needed
- 66
- Starts
- 2017-03-21
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2026-05-01
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada (enrolling)
- Skåne University Hospital — Malmö, Skåne County, Sweden (enrolling)
- Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust — London, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.